Abcam (ABCM) FCF Margin % : 2.76% (As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Abcam FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Abcam's Free Cash Flow for the six months ended in Jun. 2023 was $7.1 Mil. Abcam's Revenue for the six months ended in Jun. 2023 was $256.6 Mil. Therefore, Abcam's FCF Margin % for the quarter that ended in Jun. 2023 was 2.76%.

As of today, Abcam's current FCF Yield % is -0.50%.

The historical rank and industry rank for Abcam's FCF Margin % or its related term are showing as below:

ABCM' s FCF Margin % Range Over the Past 10 Years
Min: -5.45 Med: 20.16 Max: 26.43
Current: -5.45

During the past 13 years, the highest FCF Margin % of Abcam was 26.43%. The lowest was -5.45%. And the median was 20.16%.

ABCM's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -143.92 vs ABCM: -5.45

Abcam FCF Margin % Historical Data

The historical data trend for Abcam's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam FCF Margin % Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

FCF Margin %

Get a 7-Day Free Trial

21.83

11.11

11.47

10.50

-3.48

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															5.97	-	7.72	-15.24	2.76

Competitive Comparison of Abcam's FCF Margin %

For the Biotechnology subindustry, Abcam's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abcam's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abcam's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Abcam's FCF Margin % falls into.

Abcam FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Abcam's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-15.348	/	440.56
	=	-3.48 %

Abcam's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	7.071	/	256.566
	=	2.76 %

Abcam FCF Margin % Related Terms

Thank you for viewing the detailed overview of Abcam's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam (ABCM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (NAS:ABCM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.